Late additionFunding round
Funding round for Vaderis Therapeutics led by Life Sciences at Goldman Sachs Alternatives, TCGX
$152mRound size according to the source
SourcingClub was not involved in this transaction.
Vaderis Therapeutics closes a $152m Series B financing jointly led by Goldman Sachs Alternatives and TCGX. EQT Life Sciences participates with $17.5m, and the funds finance the global Phase 3 study of engasertib.
In context
In August 2026 it is the 2nd of 4 deals in Healthcare on the Deal-Radar.
Deal-Radar editorial team · responsible: Nick Herbig
late addition, source dated 11 Aug 2026: eqtgroup.com
Who was involved.
- Lead investor
- Life Sciences at Goldman Sachs Alternatives, TCGX
- Target
- Vaderis Therapeutics, Basel
- Type
- Funding round
- Sector
- Healthcare & Medtech
- Country
Switzerland
- Source dated
- 11/08/2026
- Round size
- $152m, according to the source
- Source
- eqtgroup.com
Deal-Radar no. 47-162 · added in Week 47/2026, first reported on 11/08/2026 · publicly reported, no guarantee · SourcingClub was not involved in this transaction. Report an error · Sources and limits
We report publicly announced information and link the source; we accept no liability for its accuracy. No offer and no investment, legal or tax advice. The operators of linked pages are responsible for their content. We correct errors as soon as we learn of them. The context is based only on deals recorded in the Deal-Radar and is not complete.
August 2026 on the Deal-Radar.
2 of 33 deals were of the type Funding round.
- Strategic11
- Add-on6
- Buy-out4
- Carve-out3
- Succession3
- Secondary3
- Funding round2
- Insolvency1
New deals every day. By email on Mondays.
All deals of the previous week in one email, with source and adviser.




